Fulvestrant Ribosepharm 250 mg Injektionslösung in einer Fertigspritze

DRUG2 trials

Sponsors

Exscientia AI Limited, Terremoto Biosciences Inc.

Conditions

Advanced solid tumorsSolid Tumours

Phase 1

A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors

RecruitingCTIS2023-508227-13-00

Exscientia AI LimitedAdvanced solid tumors

Start: 2023-06-19Target: 112Updated: 2026-01-14

A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Not yet recruitingCTIS2025-525036-34-00

Terremoto Biosciences Inc.Solid Tumours

Target: 88Updated: 2026-08-20